Evidence map›Paper›PMID 36865297›Full record

ArticlemedRxiv : the preprint server for health sciences2023

Enhancer profiling identifies epigenetic markers of endocrine resistance and reveals therapeutic options for metastatic castration-resistant prostate cancer patients.

Tesa M Severson, Yanyun Zhu, Stefan Prekovic, Karianne Schuurman, Holly M Nguyen, Lisha G Brown, Sini Hakkola, Yongsoo Kim, Jeroen Kneppers, Simon Linder and 17 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

27 authors at 9 institutions in 4 countries.

Tesa M Severson
Yanyun Zhu
Stefan Prekovic
Karianne Schuurman
Holly M Nguyen
Lisha G Brown
Sini Hakkola
Yongsoo Kim
Jeroen Kneppers
Simon Linder
Suzan Stelloo
Cor Lieftink
Michiel van der Heijden
Matti Nykter
Vincent van der Noort
Joyce Sanders
Ben Morris
Guido Jenster
Geert Jlh van Leenders
Mark Pomerantz
Matthew L Freedman
Roderick L Beijersbergen
Alfonso Urbanucci
Lodewyk Wessels
Eva Corey
Wilbert Zwart
Andries M Bergman
The Netherlands Cancer Institute · NLUniversity of Washington · USTampere University · FIBroad Institute · USErasmus MC · NLErasmus MC Cancer Institute · NLHarvard University · USOslo University Hospital · NORadboud University Nijmegen · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Androgen Receptor (AR) signaling inhibitors, including enzalutamide, are treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC), but resistance inevitably develops. Using metastatic samples from a prospective phase II clinical trial, we epigenetically profiled enhancer/promoter activities with H3K27ac chromatin immunoprecipitation followed by sequencing, before and after AR-targeted therapy. We identified a distinct subset of H3K27ac-differentially marked regions that associated with treatment responsiveness. These data were successfully validated in mCRPC patient-derived xenograft models (PDX).

Identifiers

PMID36865297
PMCPMC9980263
OpenAlexW4322217012

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.